ALISO VIEJO, Calif., Jan. 11, 2008 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO), a company that manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, today announced that Hologic and its wholly-owned subsidiary, Cytyc Corporation, had filed a lawsuit against SenoRx in the United States District Court, Northern District of California, San Jose Division. The complaint generally alleges patent infringement of certain Hologic brachytherapy patent claims seeking unspecified monetary damages and an injunction against SenoRx for infringement of certain named Hologic patents.
SenoRx has reviewed the claims made by Hologic, is confident in its proprietary intellectual property and intends to vigorously defend itself.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its flagship EnCor(r) system and Contura(tm) MLB. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. With 18 products having received FDA 510(k) clearance across the continuum of breast care, SenoRx is developing additional minimally invasive products for diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3605
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning SenoRx's plans to defend the lawsuit and its intellectual property are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on risk factors relating to SenoRx's intellectual property are in its prospectus dated March 29, 2007 and its most recent quarterly report on Form 10-Q, in each case as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.